Christina Froiland, PA
Medical · Anchorage, AKNPI 1487874913
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AbbVie at 51.7% of the total. Reporting peaked in 2024 at $13,442 and has fallen 70.5% since, to $3,965 in 2025. Among medical clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $58.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- LEO Pharma Inc.$2K
- UCB, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$947
- Johnson & Johnson$777
- plus $4K from 22 others
What the payments were for
- Consulting fees$4,04818%
- Speaking & faculty fees$5,80026%
- Travel & lodging$3,39315%
- Food & beverage$8,49538%
- Education$6923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 151 | $11,602 |
| LEO Pharma Inc. | 13 | $2,183 |
| UCB, Inc. | 12 | $1,453 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,343 |
| E.r. Squibb & Sons, L.L.C. | 16 | $947 |
| Johnson & Johnson | 24 | $777 |
| Novartis | 35 | $739 |
| Sanofi | 18 | $619 |
| Arcutis Biotherapeutics, Inc. | 11 | $565 |
| Lilly USA, LLC | 39 | $530 |
| Sun Pharmaceutical Industries Inc. | 16 | $352 |
| Dermavant Sciences, Inc. | 4 | $208 |
| Sanofi-aventis U.S. LLC | 2 | $180 |
| Incyte Corporation | 2 | $145 |
| Pfizer | 7 | $141 |
| Novo Nordisk | 7 | $116 |
| Janssen Scientific Affairs, LLC | 3 | $103 |
| Axogen | 1 | $83 |
| Genentech USA, Inc. | 1 | $80 |
| Amgen | 3 | $64 |
| GSK | 1 | $49 |
| Exact Sciences | 2 | $42 |
| Galderma Laboratories, L.p. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,428 in reported general payments places this provider in the 95th percentile of 140 medical providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 11 | $1,265 |
| Ketoconazole | 15 | $201 |
Paid to pharmacies, not to this prescriber.
Other medical in Anchorage
- Adrian GianiAnchorage$6K
- Ivy WeaklandAnchorage$4K
- Hope McGrattyAnchorage$4K
- Kimberly KinnebrewAnchorage$4K
- Jaime ZipsirAnchorage$4K
- Jeffrey StubblefieldAnchorage$4K
- Jennifer FayetteAnchorage$3K
- Eric SuojaAnchorage$3K
- Stephanie WettinAnchorage$3K
- Hailey LankfordAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.